menu search

GRPH / Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation

Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation
Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in gene therapy. I discuss why I believe GRPH is a prime candidate for the Compounding Healthcare “Bio Boom” Portfolio. Read More
Posted: Dec 9 2022, 21:19
Author Name: Seeking Alpha
Views: 103141

GRPH News  

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

By Zacks Investment Research
January 10, 2023

Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround

Graphite Bio, Inc. (GRPH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreeme more_horizontal

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

By Benzinga
January 10, 2023

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. more_horizontal

Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation

By Seeking Alpha
December 9, 2022

Graphite Bio: Underfollowed Gene Editing Play At An Attractive Valuation

Graphite Bio has lost roughly 60% of its value over the past twelve months and is trading with a negative enterprise value despite its prospects in ge more_horizontal


Search within

Pages Search Results: